Malaria vaccine trial conducted in Equatorial Guinea

Malaria vaccine trial hosted in Equatorial Guinea
Malaria vaccine trial hosted in Equatorial Guinea | Courtesy of
The first clinical trial of PfSPZ, a novel malaria vaccine developed by a U.S. biotechnology company called Sanaria, was hosted in Equatorial Guinea.

There were a total of three volunteers in the trial, which occurred in the La Paz Medical Center in Sipopo.

The vaccine provokes a strong immune response that is intended to fight against the parasite responsible for malaria.

Early tests suggest that the new drug may be the safest and most efficient malaria vaccine on the market.

Equatorial Guinea is the second country located in Africa to agree to sponsor a clinical trial for a malaria vaccine. The disease has reached endemic proportions in central and western regions of Africa.

The Equatorial Guinean government is using education, spraying and chemically treated mosquito nets to fight the illness. Experts estimate that approximately $3 million has been invested by the Equatorial Guinean government to fund the Fight Malaria Program. The program was previously used to reduce the rates of the illness on Bioko island.

The trial is the result of partnerships between the Ministry of Health and Social Welfare in Equatorial Guinea, Ifakara Health Institute (IHI), Sanaria, the La Paz Medical Center, Noble Energy, Marathon Equatorial Guinea Production Limited and Medical Care Development International (MCDI).